About Enzymotec Ltd
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ENZY
- Previous Close: $9.05
- 50 Day Moving Average: $8.29
- 200 Day Moving Average: $7.25
- 52-Week Range: $5.20 - $9.32
- Trailing P/E Ratio: 84.58
- Foreward P/E Ratio: 20.11
- P/E Growth: 1.02
- Market Cap: $205.97M
- Outstanding Shares: 22,759,000
- Beta: 1.26
- Net Margins: 4.82%
- Return on Equity: 1.95%
- Return on Assets: 1.78%
Companies Related to Enzymotec Ltd:
- Current Ratio: 7.40%
- Quick Ratio: 5.00%
What is Enzymotec Ltd's stock symbol?
Enzymotec Ltd trades on the NASDAQ under the ticker symbol "ENZY."
Where is Enzymotec Ltd's stock going? Where will Enzymotec Ltd's stock price be in 2017?
3 equities research analysts have issued 1-year target prices for Enzymotec Ltd's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Enzymotec Ltd's stock price to reach $8.00 in the next twelve months.
When will Enzymotec Ltd announce their earnings?
Enzymotec Ltd is scheduled to release their next quarterly earnings announcement on Wednesday, May, 17th 2017.
What are analysts saying about Enzymotec Ltd stock?
Here are some recent quotes from research analysts about Enzymotec Ltd stock:
- Jefferies Group LLC analysts commented, "Enzymotec has been pressured by a shifting regulatory environment and lackluster demand even as it has accelerated investment in Vaya. Regulatory changes will continue to ripple through the supply chain in 2H17-2018. We expect shares to remain range-bound absent an improvement in end markets and sustained profitability in Vaya. Clarity around strategic opportunities in InFat and the pending CEO transition would help reduce its risk profile." (2/23/2017)
According to Zacks Investment Research, "Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. " (1/17/2017)
Who owns Enzymotec Ltd stock?
Enzymotec Ltd's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Paulson & CO. Inc. (18.48%), Janus Capital Management LLC (1.27%), Renaissance Technologies LLC (1.27%), FMR LLC (0.37%), Menta Capital LLC (0.22%) and State Street Corp (0.09%).
Who sold Enzymotec Ltd stock? Who is selling Enzymotec Ltd stock?
Enzymotec Ltd's stock was sold by a variety of institutional investors in the last quarter, including Menta Capital LLC.
Who bought Enzymotec Ltd stock? Who is buying Enzymotec Ltd stock?
Enzymotec Ltd's stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Renaissance Technologies LLC and State Street Corp.
How do I buy Enzymotec Ltd stock?
Shares of Enzymotec Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Enzymotec Ltd stock cost?
One share of Enzymotec Ltd stock can currently be purchased for approximately $9.05.